Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
defactinib (VS-6063)
i
Other names:
VS-6063, PF-04554878, PF-4554878
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(8)
News
Trials
Company:
Verastem
Drug class:
FAK inhibitor
Related drugs:
‹
LY294002 (7)
AZD0530 (7)
VS-4718 (5)
APG-2449 (4)
IN10018 (3)
GSK2256098 (1)
PF-562271 (1)
SY-707 (1)
CEP-37440 (0)
FAK-JAK 2 dual Inhib (0)
NVP-TAE226 (0)
PF-573228 (0)
LY294002 (7)
AZD0530 (7)
VS-4718 (5)
APG-2449 (4)
IN10018 (3)
GSK2256098 (1)
PF-562271 (1)
SY-707 (1)
CEP-37440 (0)
FAK-JAK 2 dual Inhib (0)
NVP-TAE226 (0)
PF-573228 (0)
›
Associations
(8)
News
Trials
VERI cancer hierarchy
Reset Filters
KRAS wild-type
Ovarian Cancer
KRAS wild-type
Ovarian Cancer
VS-6766 + VS-6063
Sensitive: B - Late Trials
VS-6766 + VS-6063
Sensitive
:
B
VS-6766 + VS-6063
Sensitive: B - Late Trials
VS-6766 + VS-6063
Sensitive
:
B
KRAS G12V
Ovarian Serous Adenocarcinoma
KRAS G12V
Ovarian Serous Adenocarcinoma
VS-6766 + VS-6063
Sensitive: C2 – Inclusion Criteria
VS-6766 + VS-6063
Sensitive
:
C2
VS-6766 + VS-6063
Sensitive: C2 – Inclusion Criteria
VS-6766 + VS-6063
Sensitive
:
C2
KRAS mutation
Ovarian Cancer
KRAS mutation
Ovarian Cancer
VS-6766 + VS-6063
Sensitive: C2 – Inclusion Criteria
VS-6766 + VS-6063
Sensitive
:
C2
VS-6766 + VS-6063
Sensitive: C2 – Inclusion Criteria
VS-6766 + VS-6063
Sensitive
:
C2
KRAS G12V
Non Small Cell Lung Cancer
KRAS G12V
Non Small Cell Lung Cancer
VS-6766 + VS-6063
Sensitive: C2 – Inclusion Criteria
VS-6766 + VS-6063
Sensitive
:
C2
VS-6766 + VS-6063
Sensitive: C2 – Inclusion Criteria
VS-6766 + VS-6063
Sensitive
:
C2
KRAS G12V
Ovarian Cancer
KRAS G12V
Ovarian Cancer
VS-6766 + VS-6063
Sensitive: C2 – Inclusion Criteria
VS-6766 + VS-6063
Sensitive
:
C2
VS-6766 + VS-6063
Sensitive: C2 – Inclusion Criteria
VS-6766 + VS-6063
Sensitive
:
C2
KRAS G12D
Ovarian Serous Adenocarcinoma
KRAS G12D
Ovarian Serous Adenocarcinoma
VS-6766 + VS-6063
Sensitive: C3 – Early Trials
VS-6766 + VS-6063
Sensitive
:
C3
VS-6766 + VS-6063
Sensitive: C3 – Early Trials
VS-6766 + VS-6063
Sensitive
:
C3
KRAS G12A
Ovarian Serous Adenocarcinoma
KRAS G12A
Ovarian Serous Adenocarcinoma
VS-6766 + VS-6063
Sensitive: C3 – Early Trials
VS-6766 + VS-6063
Sensitive
:
C3
VS-6766 + VS-6063
Sensitive: C3 – Early Trials
VS-6766 + VS-6063
Sensitive
:
C3
KRAS G12C
Non Small Cell Lung Cancer
KRAS G12C
Non Small Cell Lung Cancer
sotorasib + VS-6766 + VS-6063
Sensitive: D – Preclinical
sotorasib + VS-6766 + VS-6063
Sensitive
:
D
sotorasib + VS-6766 + VS-6063
Sensitive: D – Preclinical
sotorasib + VS-6766 + VS-6063
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login